Recombinant Human IFN-alpha I/IFN17 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11082-IF

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11082-IF-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P01571.2

Conjugate

Unconjugated

Applications

Bioactivity

View all IFN-alpha I Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha I protein
Cys24-Asp189

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
The ED50 for this effect is 1.00-20.0 pg/mL.

Scientific Data Images for Recombinant Human IFN-alpha I/IFN17 Protein, CF

Recombinant Human IFN‑ alpha1 Protein Bioactivity.

Recombinant Human IFN-alpha1 Protein (Catalog # 11082-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 1.00-20.0 pg/mL

Recombinant Human IFN‑ alpha1 Protein SDS-PAGE.

2 μg/lane of Recombinant Human IFN‑ alpha1 Protein (Catalog # 11082-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-22 kDa.

Formulation, Preparation and Storage

11082-IF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha I

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical-bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). There is not a mouse homolog for IFNA17, but mature human IFNA17 shares 58% aa sequence identity with chimpanzee IFNA17. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection (8). IFNA17 has been shown to be potent against HIV-1 activity (9). Human IFNA17 is the only IFNA subtype identified with antiviral activity but a reduced ability to activate NK cells (10). A mutation in IFNA17, Ile184Arg, is associated with an increased risk for cervical cancer (11).

References

  1. Pestka S, et al. (1987) Annu Rev Biochem. 56:727.
  2. Goeddel, D.V. et al. (1980) Nature 287:411.
  3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
  4. Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
  5. Wittling, M.C. et al. (2021) Front Immunol. 11:605673.
  6. van Pesch, V. et al. (2004) J. Virol. 78:8219.
  7. James C.M. et al. (2007) Vaccine. 25(10):1856.
  8. Moll, H.P. et al. (2011) Cytokine. 53:52.
  9. Lavender, K.J. et al. (2016) J Virol. 90:6001.
  10. Ortaldo, J.R. et al. (1984) PNAS 81:4926.
  11. Kim, J.W. et al. (2003) Cancer Lett. 189:183.

Long Name

Interferon alpha I

Alternate Names

IFNA17, IFNalpha I

Entrez Gene IDs

3451 (Human)

Gene Symbol

IFNA17

UniProt

P01571.2

Additional IFN-alpha I Products

Product Documents for Recombinant Human IFN-alpha I/IFN17 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human IFN-alpha I/IFN17 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.